Related Experiment Video
Updated: Dec 9, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis
Ling Nie1, Yong Liu1, Bo Zhang1
1Department of Nephrology, Institute of Nephrology of Chongqing and Kidney Center of PLA, Xinqiao Hospital, Army Medical University (The Third Military Medical University), Chongqing, China.
Background:
Renal interstitial fibrosis is characterized by the accumulation of extracellular matrix proteins, which is a common feature of chronic kidney diseases.
Summary:
Increasing evidence has shown the aberrant expression of histone deacetylases (HDACs) in the development and progression of renal fibrosis, suggesting the possibility of utilizing HDAC inhibitor (HDACi) as therapeutics for renal fibrosis. Recent studies have successfully demonstrated the antifibrotic effects of HDACis in various animal models, which are associated with multiple signaling pathways including TGF-β signaling, EGRF signaling, signal transducer and activator of transcription 3 pathway, and JNK/Notch2 signaling. This review will focus on the utilization of HDACi as antifibrotic agents and its relative molecular mechanisms.
Key Messages:
HDACis have shown promising results in antifibrotic therapy, and it is rational to anticipate that HDACis will improve clinical outcomes of renal fibrosis in the future.
Insights
Histone deacetylase inhibitors (HDACis) show promise in treating kidney fibrosis by targeting extracellular matrix accumulation. These agents demonstrate antifibrotic effects through various molecular pathways, offering potential therapeutic benefits for chronic kidney diseases.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Renal interstitial fibrosis, marked by extracellular matrix accumulation, is a hallmark of chronic kidney diseases.
- Aberrant expression of histone deacetylases (HDACs) is implicated in the development and progression of renal fibrosis.
Purpose of the Study:
- To review the therapeutic potential of histone deacetylase inhibitors (HDACis) as antifibrotic agents for renal fibrosis.
- To elucidate the molecular mechanisms underlying the antifibrotic effects of HDACis.
Main Methods:
- Review of recent studies on HDAC inhibitors in animal models of renal fibrosis.
- Analysis of signaling pathways modulated by HDACis, including TGF-β, EGFR, STAT3, and JNK/Notch2.
Main Results:
- HDACis have demonstrated significant antifibrotic effects in various preclinical models.
- These effects are associated with the modulation of key fibrotic signaling pathways.
Conclusions:
- HDAC inhibitors represent a promising therapeutic strategy for renal fibrosis.
- Further research and clinical application of HDACis are anticipated to improve outcomes in chronic kidney disease patients.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Diuretics
Acute Kidney Injury II: Pathophysiology

